Clinical Trial Detail

NCT ID NCT02471716
Title Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Five Prime Therapeutics, Inc.
Indications

tenosynovial giant cell tumor

Therapies

Cabiralizumab

Age Groups: adult

No variant requirements are available.